1. Home
  2. PLBC vs AUTL Comparison

PLBC vs AUTL Comparison

Compare PLBC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plumas Bancorp

PLBC

Plumas Bancorp

HOLD

Current Price

$50.46

Market Cap

340.7M

Sector

Finance

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.56

Market Cap

407.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBC
AUTL
Founded
1980
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
340.7M
407.2M
IPO Year
2002
2025

Fundamental Metrics

Financial Performance
Metric
PLBC
AUTL
Price
$50.46
$1.56
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$57.67
$8.50
AVG Volume (30 Days)
52.8K
1.2M
Earning Date
04-15-2026
05-14-2026
Dividend Yield
2.60%
N/A
EPS Growth
N/A
N/A
EPS
4.54
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
$25.59
$80.32
Revenue Next Year
$5.15
$53.96
P/E Ratio
$11.28
N/A
Revenue Growth
N/A
496.00
52 Week Low
$39.70
$1.15
52 Week High
$54.58
$2.70

Technical Indicators

Market Signals
Indicator
PLBC
AUTL
Relative Strength Index (RSI) 46.14 56.28
Support Level $40.58 $1.22
Resistance Level $52.61 $1.69
Average True Range (ATR) 1.30 0.08
MACD -0.17 -0.00
Stochastic Oscillator 6.49 57.63

Price Performance

Historical Comparison
PLBC
AUTL

About PLBC Plumas Bancorp

Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: